ADMA Biologics, Inc.
General ticker "ADMA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $4.3B (TTM average)
ADMA Biologics, Inc. does not follow the US Stock Market performance with the rate: -10.4%.
Estimated limits based on current volatility of 1.9%: low 19.49$, high 20.25$
Factors to consider:
- Total employees count: 685 (+9.8%) as of 2024
- US accounted for 94.8% of revenue in the fiscal year ended 2023-12-31
- Top business risk factors: Market volatility, Profitability concerns, Pandemic risks, Geopolitical risks, Regulatory and compliance
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [12.39$, 24.75$]
- 2025-12-31 to 2026-12-31 estimated range: [12.02$, 24.23$]
Financial Metrics affecting the ADMA estimates:
- Positive: with PPE of 35.1 at the end of fiscal year the price was neutral
- Positive: Operating profit margin, % of 32.59 > 18.64
- Negative: negative Industry operating cash flow (median)
- Positive: Return on assets ratio (scaled to [-100,100]) of 28.80 > 6.04
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: 0.33 < Operating cash flow per share per price, % of 2.90
- Negative: 0 < Inventory ratio change, % of 0.04
- Negative: Industry earnings per price (median), % of -16.34 <= 0
Short-term ADMA quotes
Long-term ADMA plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $154.08MM | $258.21MM | $426.45MM |
| Operating Expenses | $193.44MM | $236.58MM | $287.47MM |
| Operating Income | $-39.37MM | $21.63MM | $138.98MM |
| Non-Operating Income | $-26.54MM | $-49.87MM | $-13.27MM |
| Interest Expense | $19.28MM | $25.03MM | $13.93MM |
| R&D Expense | $3.61MM | $3.30MM | $1.81MM |
| Income(Loss) | $-65.90MM | $-28.24MM | $125.71MM |
| Taxes | $0.00MM | $0.00MM | $-71.96MM |
| Profit(Loss)* | $-65.90MM | $-28.24MM | $197.67MM |
| Stockholders Equity | $151.97MM | $135.21MM | $349.02MM |
| Assets | $348.46MM | $329.18MM | $488.68MM |
| Operating Cash Flow | $-59.51MM | $8.80MM | $118.67MM |
| Capital expenditure | $13.91MM | $4.98MM | $8.57MM |
| Investing Cash Flow | $-13.91MM | $-4.98MM | $-8.57MM |
| Financing Cash Flow | $108.85MM | $-38.99MM | $-58.30MM |
| Earnings Per Share** | $-0.33 | $-0.13 | $0.85 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.